首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2016年 9期 肝衰竭 => 其他 =>停用核苷和核苷酸类药物诱发HBV..
停用核苷和核苷酸类药物诱发HBV相关慢加急性肝衰竭患者的临床特点分析
Clinical features of HBV-associated acute-on-chronic liver failure induced by discontinuation of nucleoside analogues
文章发布日期:2016年08月08日  来源:  作者:刘晓燕, 陈 婧, 肖 珑, 等  点击次数:771次  下载次数:188次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的探讨停用核苷和核苷酸类药物导致HBV相关慢加急性肝衰竭(HBV-ACLF)患者的临床特点。方法回顾性分析2014年1月-2016年 4月在解放军第三○二医院明确诊断为HBV-ACLF的患者698例,其中因停药导致ACLF的患者150例(停药组),初次发病未行抗病毒治疗患者396例(初次未治组),因其他原因导致ACLF的患者152例。统计所有患者发病诱因、基础疾病、家族史、乙型肝炎血清标志物、预后及是否为首次发病,对停用核苷和核苷酸类药物患者记录所用药物、停药至发生肝衰竭时间。计数资料组间比较采用χ2检验。结果698例患者中355例(50.86%)有慢性乙型肝炎(CHB)家族史,停药组患者中93例(6200%)有CHB家族史。停药组150例患者中27例(1800%)为慢性肝炎基础,其中12例(44.44%)有CHB家族史,低于整体水平(χ2=257, P=0.07);123例(8200%)为肝硬化(代偿期)基础,其中81例(65.85%)有CHB家族史,显著高于整体水平(χ2=48.77, P<0001)。停药后1年内发病者占77.33%(116/150),21.33%(32/150)患者在第2年内发病。HBeAg阴性患者占4733%(71/150)。停药组、初次未治组中慢性肝炎基础患者的治愈、好转率均高于肝硬化基础患者(停药组:88.89% vs 5366%, χ2=11.450, P=0.001;初次未治组:71.79% vs 5950%, χ2=5355, P=0.021)。结论停用核苷和核苷酸类药物诱发肝衰竭的比例上升。长期抗病毒治疗,尤其对于肝硬化患者十分重要。
【Abstract】:ObjectiveTo investigate the clinical features of patients with HBV-associated acute-on-chronic liver failure (HBV-ACLF) induced by the discontinuation of necleos(t)ide analogues. MethodsA retrospective analysis was performed for 698 patients with a definite diagnosis of HBV-ACLF in The 302 Hospital of PLA from January 2014 to April 2016, and among these patients, 150 (discontinuation group) had acute-on-chronic liver failure (ACLF) induced by discontinuation, 396 (previously untreated group) had not received antiviral therapy when they developed this disease for the first time, and the other 152 patients with ACLF caused by other reasons were enrolled as controls. The causative factors, underlying diseases, family history, serum hepatitis B markers, prognosis, and initial onset were summarized, and the drugs used and discontinuation time were recorded for patients who stopped taking necleos(t)ide analogues. The chi-square test was used for the comparison of categorical data between groups. ResultsAmong the 698 patients, 355(5086%) had a family history of chronic hepatitis B (CHB), and 93 patients (6200%) in the discontinuation group had a family history of CHB. Among the 150 patients in the discontinuation group, 27 (1800%) had an underlying disease of chronic hepatitis, among whom 12 (4444%) had a family history of CHB, which was significantly lower than the overall level (χ2=2.57, P=0.07); 123 (8200%) had an underlying disease of liver cirrhosis (compensated), among whom 81 (65.85%) had a family history of CHB, which was significantly higher than the overall level (χ2=48.77, P<0.001). Of all the patients in the discontinuation group, 77.33% (116/150) developed the disease within 1 year after discontinuation, and 21.33% (32/150)developed the disease during the second year after discontinuation. The HBeAg-negative patients accounted for 47.33% (71/150). In the discontinuation group and previously untreated group, the patients with an underlying disease of chronic hepatitis showed a significantly higher cure and improvement rate than those with an underlying disease of liver cirrhosis (the discontinuation group: 88.89% vs 53.66%, χ2=11.450, P=0.001; the previously untreated group: 71.79% vs 59.50%, χ2=5.355, P=0021). ConclusionDiscontinuation of necleos(t)ide analogues results in an increased proportion of patients with liver failure. Long-term antiviral therapy is very important, especially for patients with liver cirrhosis.
【关键字】:肝功能衰竭; 肝炎病毒, 乙型; 核苷类; 核苷酸类
【Key words】:liver failure; hepatitis B virus; nucleosides; nucleotides
【引证本文】:刘晓燕, 陈婧, 肖珑, 等. 停用核苷和核苷酸类药物诱发HBV相关慢加急性肝衰竭患者的临床特点分析[J]. 临床肝胆病杂志, 2016, 32(9): 1766-1769.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号